Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Additional Off-Label Uses of rFVIIa Requiring Future Research
Medical conditions include: cancer-related conditions, gastrointestinal bleeding not related to liver disease, hematopoietic stem cell transplantation, liver disease (other than transplantation), neonatal conditions (beyond cardiac surgery), obstetrical conditions, primary clotting disorders (other than hemophilia), pulmonary conditions (e.g., pulmonary hemorrhage, pulmonary transplantation), and secondary clotting disorders (e.g., complications of warfarin anticoagulation).
- Yank V, Tuohy CV, Logan AC, et al. Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care, Comparative Effectiveness Review 21 (Prepared by Stanford–UCSF Evidence-based Practice Center under Contract No. 290-02-0017). Rockville, MD: Agency for Healthcare Research and Quality; May 2010. AHRQ Publication No. 10-EHC030-EF.
Your slide tray is being processed.